Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ENSEMBLE

- PMLiVE

England to end COVID-19 isolation laws and mass free testing

From 24 February, all COVID-19 restrictions will end in England and from 1 April, all free mass testing will finish

- PMLiVE

COVID-19 booster to be made available to those over 75 and high risk adults and children

Around 7.2 million people living in the UK aged over 75 – having already had their primary course of COVID-19 vaccines – will be eligible for the booster

- PMLiVE

Eli Lilly’s Omicron drug treatment gets emergency use authorisation from FDA

The drug can be used to treat adults with mild-to-moderate COVID-19, and children aged 12 or older, in specific emergency cases in non-hospital settings

- PMLiVE

WHO issues prequalification for Roche’s Actemra/RoActemra for severe or critical COVID-19

The prequalification confirms the treatment meets WHO’s standards for quality, effectiveness and safety

- PMLiVE

Merck and Ridgeback fulfil US deal for molnupiravir

Over three million courses of the investigational oral antiviral COVID-19 treatment have been supplied

- PMLiVE

Celltrion submits application for inhaled COVID-19 antibody treatment

A global phase 3 clinical study will evaluate the inhaled antibody cocktail treatment for patients with mild-to-moderate COVID-19 symptoms

- PMLiVE

Six million patients affected by delay to NHS England’s plans to address COVID-19 backlog

UK’s health and social care secretary Sajid Javid said that the number of patients on these hospital waiting lists would increase before beginning to fall

- PMLiVE

MHRA issues CMA for Novavax COVID-19 vaccine

Nuvaxovid offers up to 89% protection against COVID-19

- PMLiVE

New Omicron subvariant appears more transmissible but no more severe than original Omicron strain

The new subvariant is already emerging as a dominant strain in Denmark, the Philippines, Nepal, Qatar and India

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Moderna begins phase 2 trial of Omicron-specific booster

The study will include two groups, with approximately 300 people in each group

- PMLiVE

Janssen’s Tremfya receives positive results for active psoriatic arthritis

The drug demonstrated positive joint efficacy and ranked highest for skin clearance when compared to existing therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links